(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual revenue growth rate of 12.07% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.06%.
Neurocrine Biosciences's revenue in 2026 is $3,701,700,000.On average, 32 Wall Street analysts forecast NBIX's revenue for 2026 to be $411,656,221,081, with the lowest NBIX revenue forecast at $385,238,155,258, and the highest NBIX revenue forecast at $443,944,968,198. On average, 31 Wall Street analysts forecast NBIX's revenue for 2027 to be $474,108,123,812, with the lowest NBIX revenue forecast at $439,795,003,835, and the highest NBIX revenue forecast at $539,191,711,261.
In 2028, NBIX is forecast to generate $525,122,319,884 in revenue, with the lowest revenue forecast at $472,387,406,881 and the highest revenue forecast at $614,093,507,081.